Big movers on D-Street: What should investors do with TCS, Natco Pharma and GRSE?

Domestic markets closed lower despite the RBI hinting at a rate cut. TCS is showing strong technical resilience and poised for an upward reversal, making it a ‘buy on dips’ candidate. Natco Pharma is in a healthy consolidation phase with potential targets of Rs 1,650–1,720.